Clinical trials: Resectable NSCLC
Sintilimab, Lung Cancer
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
primary purpose：Observe the pathological complete response rate (PCR) of postoperative tumor tissue resection and evaluate the safety of the treatment process.
- Conditions
- Sintilimab, Lung Cancer, Anlotinib, Chemotherapy
- Trial name
- NCT05400070
- Testing
- Neoadjuvant therapy 1
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
Lung Cancer, Nonsmall Cell
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles)…
- Trial name
- NCT04638582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Non-Small Cell Carcinoma of Lung, Gut Microbiomes
Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC
Locally advanced lung cancer (LALC) has poor prognosis despite multimodal therapies. Neoadjuvant chemoimmunotherapy is now standard for resectable stage II-IIIB NSCLC, but patient responses vary.
- Conditions
- Non-Small Cell Carcinoma of Lung, Gut Microbiomes, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07752589
- Testing
- Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital